aidsmap
@aidsmap
aidsmap (previously known as NAM aidsmap) is now hosted by Terrence Higgins Trust, an HIV charity based in the United Kingdom.
Our final news summary from #IAS2025 is out now incl: -Does 6-monthly PrEP have a future after funding collapse? -HIV integration sparks fierce debate -US funding cuts & HIV testing/treatment -Antibodies shows promise in the search for a cure aidsmap.com/bulletin/confe… @iasociety

News from #IAS2025: Stepping into the AI-driven future of HIV prevention and care @iasociety aidsmap.com/news/jul-2025/…

News from #IAS2025: Is HIV integration a response or a death sentence? Communities demand answers @iasociety aidsmap.com/news/jul-2025/…

News from #IAS2025: Does six-monthly PrEP have a future following the collapse of global HIV funding? @iasociety aidsmap.com/news/jul-2025/…

News from #IAS2025: Children born with HIV have persistent inflammation markers linked to heart disease aidsmap.com/news/jul-2025/… @iasociety

Smoking is one of the most important causes of illness and death in HIV-positive people. For people with HIV who are undetectable, smoking has a much greater impact on life expectancy than HIV. aidsmap.com/about-hiv/smok…
News from #IAS2025: The US cuts challenge African funders and governments to provide new models of PrEP access @iasociety aidsmap.com/news/jul-2025/…

News from #IAS2025: Conflicts and humanitarian crises create new HIV vulnerabilities @iasociety aidsmap.com/news/jul-2025/…
News from #IAS2025: US funding cuts cause immediate drops in numbers testing and on HIV treatment @iasociety aidsmap.com/news/jul-2025/…

All anti-HIV drugs try to prevent HIV infecting new cells, but different types of drugs do it in different ways. Find out how treatment works on our illustrated page, or download it as a PDF leaflet aidsmap.com/about-hiv/basi…
News from #IAS2025: Broadly neutralising antibodies plus immune modulator may delay HIV rebound @iasociety aidsmap.com/news/jul-2025/…

Our 2nd #IAS2025 news summary is out now, incl: -Monthly oral PrEP pill -Injectable ART works for people with adherence challenges -ART switches don't reduce weight -PEPFAR cuts & PrEP aidsmap.com/bulletin/confe… @iasociety

News from #IAS2025: Injectable HIV treatment works for people with poor HIV control in Africa @iasociety aidsmap.com/news/jul-2025/…
News from #IAS2025: Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding @iasociety aidsmap.com/news/jul-2025/…

"The theme of #AIDS2026 is Rethink. Rebuild. Rise (#RethinkRebuildRise): #Rethink what leadership looks like. #Rebuild the architecture and resilience of the HIV response. #Rise to meet this moment with courage, clarity, and compassion – together." - @BGrinsztejn #IAS2025
News from #IAS2025: Intermittent HIV treatment dosing may be a response to the funding crisis, but adolescent study raises concerns @iasociety aidsmap.com/news/jul-2025/…

News from #IAS2025: Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year @iasociety aidsmap.com/news/jul-2025/…

Want to keep up to date with the latest HIV news? Subscribe to aidsmap bulletins and we'll share HIV research and developments from around the world and news from international HIV conferences. aidsmap.com/subscribe

News from #IAS2025: Treatment changes do not reduce weight in people with HIV @iasociety aidsmap.com/news/jul-2025/…

⚡ Your words have power. Choose them with care: ✅"People living with HIV" & not ❌ "Infected people" ✅"HIV acquisition" & not ❌ "Infection" ✅"A person who has acquired HIV" & not ❌ "Caught HIV" 🌐 Learn more & join us: iasociety.org/language-matte… #IAS2025 #PutPeopleFirst